
Keywords: prodrugs; percutaneous; permeability; phase I enzyme; skin; metabolism; mRNA; BChE; butyrylcholinesterase; BNPP; bis-p-nitrophenyl phosphate; CES; carboxylesterase; FXD; fexofenadine; hCE1; human carboxylesterase 1; hCE2; human carboxylesterase 2; HEPES;